DOJ’s Largest Health Care Fraud Enforcement Action

Overview

On June 23, 2026, the U.S. Department of Justice announced the 2026 National Health Care Fraud Takedown—the largest coordinated health care fraud enforcement action in the Department’s history. The scope of the action is extraordinary and signals an escalation in both the tools and the institutional architecture the federal government is deploying against health care fraud.

Key Figures

• 455 defendants charged, including 90 doctors and other licensed medical professionals, for alleged health care fraud and opioid-diversion schemes involving over $6.5 billion in false claims.
• Cases filed in 56 federal districts spanning 45 U.S. states and territories, with 50 state Medicaid Fraud Control Units (MFCUs) participating—the most in Department history.
• Over $182 million seized in cash, luxury vehicles, jewelry, and other assets.
• CMS suspended 1,079 providers and revoked billing privileges for 1,403 providers.
• Civil enforcement: 
  • 48 Civil Monetary Payment settlements exceeding $73 million
  • More than 1,400 provider exclusions
  • 25 HHS-OIG actions under the Civil Monetary Penalties Law seeking more than $10 billion to the Medicare Trust Fund
• 928 DEA administrative cases seeking revocation of controlled-substance authority since October 1, 2025.
• DOJ characterizes health care fraud as “a top white-collar priority.”

This takedown demonstrates that the federal government is investing unprecedented resources – data analytics, AI tools, cross-agency data sharing, and a new dedicated enforcement division – in the detection and prosecution of health care fraud. Providers, executives, and investors should take notice.

Enforcement Highlights

Advanced Data Analytics and AI-Driven Detection

A defining feature of the 2026 Takedown is the DOJ’s emphasis on sophisticated data analytics and artificial intelligence as central enforcement tools:

• The Health Care Fraud Unit’s Data Fusion Center and its new Financial Intelligence Review Team were spotlighted as key operational capabilities.
• The Financial Intelligence Review Team’s first prosecution involved a $67 million Illinois Medicaid behavioral health fraud scheme.
• DOJ’s Fraud Division and CMS entered an agreement giving the Fraud Division cloud computing space within the CMS Integrated Data Repository, enabling deployment of advanced algorithms and AI tools to identify anomalous billing patterns.
• Additional data-sharing agreements with DHS and the FTC are designed to “break down data silos” across agencies.
• CMS Administrator Dr. Mehmet Oz emphasized the government’s aim to “stop fraud before payments leave the building.”

Implication: Providers should assume that billing data is subject to real-time algorithmic surveillance. Outlier billing patterns—even those with legitimate explanations—will trigger scrutiny. Proactive compliance monitoring and data self-audits are more important than ever.

New Institutional Architecture

The 2026 Takedown is supported by significant structural changes within DOJ: 

1. National Fraud Enforcement Division
   The DOJ created the National Fraud Enforcement Division on April 7, 2026, consolidating and expanding fraud-fighting resources.
2. Eliminating Fraud
   The takedown supports the White House Task Force to Eliminate Fraud, chaired by Vice President JD Vance.
3. Investigating Medicaid Fraud
   The DOJ received an enhancement to investigate Medicaid fraud nationwide, building on the recent Minnesota Health Care Fraud Takedown.

Wound Care and Allograft Fraud Schemes

A signature theme of the 2026 Takedown involves charges related to amniotic wound-care allografts:

• 11 defendants charged, including a company executive and eight medical professionals across six federal districts.
• Providers allegedly billed Medicare over $4 billion for one company’s amniotic wound allografts (with over $2 billion paid by Medicare).
• Allografts were allegedly relabeled and sold at a 2,000% mark-up—up to $1,450 per square centimeter—with alleged kickbacks of roughly 40% paid to referring providers.
• A nurse practitioner in the Southern District of Texas was charged in a $906 million scheme.
• CMS realigned payment for these products to $127 per square centimeter effective January 1, 2026.

Implication: Companies and clinicians involved in wound care products, biologics, and allografts face a concentrated enforcement risk. The combination of criminal charges, kickback allegations, and CMS payment restructuring suggests this area will remain a priority.

Patient Harm and Individual Accountability

DOJ emphasized patient harm as a driver of prosecutorial priority:

• In the Southern District of Florida, a medical director was charged in an $89 million scheme involving unnecessary cardiovascular testing on student athletes. The defendant allegedly rubber-stamped abnormal results as normal; a student athlete later died.
• 36 defendants – including 28 licensed medical professionals – charged with illegal diversion of prescription opioids and other controlled substances resulting in patient harm.

Implication: Cases involving patient injury or death carry the most severe sentencing exposure and attract the greatest prosecutorial attention. Executives and medical professionals face significant personal liability.

Medicaid Fraud: Record Scale

The 2026 Takedown includes the largest number of Medicaid fraud defendants and alleged losses in Department history:

• 295 defendants charged in connection with over $518 million in false Medicaid claims

Implication: Medicaid providers and managed-care organizations should expect intensified federal-state coordination. Medicaid fraud is no longer primarily a state-level enforcement matter.

Next Steps for Providers, Executives, and Companies

The 2026 Takedown is a clear signal that health care fraud enforcement is intensifying across all fronts – criminal, civil, and administrative. Organizations and individuals should take proactive steps now: 

1. Audit Billing Data for Statistical Anomalies
   With DOJ deploying AI tools to flag outlier billing patterns, providers should conduct internal data reviews to identify and document legitimate explanations for any claims that may appear anomalous to algorithmic surveillance.
2. Stress-Test Compensation Arrangements
   Any arrangement tying compensation to referral volume or value—especially in wound care, biologics, telemedicine, or lab services—warrants fresh Anti-Kickback Statute and Stark Law analysis in light of the enforcement patterns highlighted in this takedown.
3. Prepare for Parallel Proceedings
   A single set of facts can trigger simultaneous criminal investigation, False Claims Act exposure, CMP liability, exclusion risk, and DEA action. Counsel should be engaged early to coordinate across enforcement tracks.
4. Brief Key Personnel on Exposure
   The charging of 90 individual medical professionals —and a corporate executive—underscores that DOJ is prioritizing individual accountability. Officers, directors, and compliance leaders should understand their personal risk.

Scale LLP’s White Collar & Investigations Team

Our White Collar & Investigations practice represents health care industry clients across the full spectrum of government enforcement matters—from proactive compliance counseling through criminal defense, civil litigation, and administrative proceedings. We regularly handle:

• Grand jury subpoenas (DOJ, HHS-OIG, FBI, DEA, MFCUs), search warrants, and federal/state health care fraud investigations 
• Defense of health care fraud, Anti-Kickback Statute, and controlled-substance charges
• Executive, officer, and medical professional individual representation
• Qui tam and False Claims Act defense, Civil Monetary Penalty proceedings, and provider exclusion actions
• Internal investigations and voluntary self-disclosure strategy
• Compliance program design, Anti-Kickback/Stark analysis, and billing/coding reviews
• CMS payment suspensions, DEA registration revocations, and reinstatement proceedings